[Glucocorticoid-induced osteoporosis]

Endokrynol Pol. 2007 Mar-Apr;58(2):170-5.
[Article in Polish]

Abstract

Prolonged glucocorticoids administration is the most common cause of secondary osteoporosis. It is estimated that 30% to 50% of chronic glucocorticoids users experience vertebral or hip fractures. The highest bone loss (up to 30% in some studies) is observed in the first six months of treatment. Only a minority of patients who take chronic glucocorticoids receive optimal osteoporosis diagnosis, prevention, and/or treatment. The aim of this paper is to present the pathophysiology of glucocorticoid-induced osteoporosis, as well as some guidelines on diagnostic, preventive and therapeutic strategies for this disorder in an effort to promote the greater awareness of it.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Bone Density / drug effects*
  • Bone Density Conservation Agents / therapeutic use
  • Bone Resorption / chemically induced
  • Bone and Bones / metabolism
  • Calcium / analysis*
  • Cell Differentiation / drug effects
  • Fractures, Bone / etiology*
  • Glucocorticoids / adverse effects*
  • Glucocorticoids / therapeutic use
  • Hip Fractures
  • Humans
  • Osteoporosis / chemically induced*
  • Osteoporosis / diagnosis
  • Osteoporosis / drug therapy*

Substances

  • Bone Density Conservation Agents
  • Glucocorticoids
  • Calcium